Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for serious rare and ultra-rare genetic diseases. The company utilizes multiple modalities, including biologics, small molecules, adeno-associated virus (AAV) gene therapy, and nucleic acids, to address conditions with high unmet medical need. Its approved portfolio includes Crysvita for X-Linked Hypophosphatemia and Tumor-Induced Osteomalacia, Mepsevii for Mucopolysaccharidosis VII, Dojolvi for Long-chain Fatty Acid Oxidation Disorders, and Evkeeza for Homozygous Familial Hypercholesterolemia. The clinical pipeline features UX111 (rebisufligene etisparvovec), an AAV9 gene therapy for Sanfilippo syndrome type A, and other candidates for conditions such as Angelman syndrome. Ultragenyx serves patients in North America, the European Union, the United Kingdom, Latin America, Türkiye, Asia, and select international markets through its own commercial organization and third-party distributors. The company collaborates with partners including Kyowa Kirin, Regeneron Pharmaceuticals, and Abeona Therapeutics for the development and commercialization of its products. Founded in April 2010, the company retains global commercialization rights for most of its product candidates.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage ultragenyx.com
Sector Healthcare IR page ir.ultragenyx.com
Tags
rare diseases, gene therapy, enzyme replacement therapy, monoclonal antibodies, lysosomal storage diseases, metabolic disorders, orphan drugs, aav therapy, small molecules, nucleic acids, Crysvita, Mepsevii, Dojolvi, Evkeeza, UX111, rebisufligene etisparvovec, FAYUVI, Kyowa Kirin, Regeneron, Abeona Therapeutics, Saint Louis University, Baylor Research Institute
Press page ultragenyx.com/newsroom

Metrics

Valuation  
Market cap $ 1.556B
Market cap (USD) $ 1.556B
P/E -2.95
PEG —
P/BV -4.14
P/S 2.13
P/OCF -3.56
P/FCF -3.52
Dividend yield —
Turnover / mcap —
Returns  
ROE 718.8%
ROI —
ROIC —
Profit margin -85.4%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 95
Quality score -12.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 673M 560.23M 434.249M 363.329M 351.406M 271.03M 103.714M 51.495M 2.612M 133K — — —
Net profit -575M -569.183M -606.639M -707.421M -454.025M -186.566M -402.727M -197.611M -302.139M -245.874M -145.618M -59.802M -35.07M
Free cash flow -472M -421.679M -519.073M -496.588M -411.788M -176.125M -370.215M -294.642M -256.636M -171.163M -110.932M -46.783M -31.607M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 23 42.07 47.82 46.33 84.09 138.43 42.71 43.48 46.38 70.31 112.18 43.88 —
Price performance 12m -0.45 -0.12 0.03 -0.45 -0.39 2.24 -0.02 -0.06 -0.34 -0.37 1.56 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 5.17M 12.7M 32.8M 23.1M 28.4M 40.4M 73.4M 122M 158M
↳ YoY growth +146.3% +157.8% -29.7% +23.1% +42.3% +81.5% +66.0% +29.7%
↳ 5y CAGR +50.9% +41.9% +30.0% +46.9%
Lease liabilities (USD) — — — 37M 48.2M 42M 31.6M 43.2M 40.3M 36M
Cash and deposits (USD) 161M 100M 113M 434M 714M 308M 133M 214M 174M 421M
Intangible assets (USD) — 142M 129M 129M 131M 131M 160M 166M 178M 176M
Right-of-use assets (USD) — — — 30.3M 40.5M 34.9M 26M 23.9M 25.5M 23M
Cash flow detail
Operating cash flow (USD) -161M -254M -291M -345M -132M -339M -380M -475M -414M -466M
Purchases of property, plant and equipment (USD) -10.2M -2.79M -4.08M -24.8M -43.9M -73.1M -116M -44.3M -7.49M -6M
Purchases of intangible assets (USD) — — — — 0.00 0.00 -30M -2.5M -12.5M -15M
Change in receivables (cash effect) (USD) — -5.17M -7.58M -20.1M 9.84M -5.43M -12.1M -22.8M -33.6M -31M
Change in inventories (cash effect) (USD) — -757,000 -5.28M -4.45M -1.35M -3.12M -9.7M -6.93M -11.2M -6M
Change in payables (cash effect) (USD) 2.5M 3.46M 3.37M — — — — — — —
Income taxes paid (cash effect) (USD) — — — — — — — — — -4M
Share-based compensation (USD) 48.3M 68M 80.1M 82M 85.7M 105M 130M 135M 158M 153M
Operating cash flow before change in receivables (USD) — -249M -283M -325M -142M -333M -368M -452M -381M -435M
Free cash flow (OCF - PPE - intangibles) (USD) -171M -257M -295M -370M -176M -412M -527M -522M -434M -487M
Income detail
Research and development expense (USD) 183M 232M 294M 357M 412M 497M 706M 648M 698M 750M
↳ 5y CAGR +78.9% +60.2% +50.7% +29.1% +22.1% +25.0% +17.1% +14.3% +12.7%
Total comprehensive income (USD) -244M -309M -193M -402M -186M -456M -713M -599M -570M -573M
Comprehensive income to owners (USD) -244M -309M -193M -402M -186M -456M -713M -599M -570M -573M
Reported Feb 17, 2017 Feb 20, 2019 Feb 20, 2019 Feb 14, 2020 Feb 17, 2023 Feb 17, 2023 Feb 17, 2023 Feb 21, 2024 Feb 19, 2025 Feb 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 3, 2026

PDF Version

Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million

GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter

Two Priority Review Vouchers (PRVs) under agreement for combined sales price of $413 million

Substantial reduction of expenses and headcount underway, expected to drive at least a 50% reduction in 2027 R&D expenses vs 2025

NOVATO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended September 30, 2026, announced substantial expense reductions, and reaffirmed its guidance for 2026 revenue and 2027 profitability.

“We received two BLA approvals from the FDA within one month for our first gene therapy treatments and the launches are progressing well with growing demand for these products,” said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. “With substantial reductions in headcount and expenses, combined with two launches and continued growth in our base business, we expect meaningful profitability in 2027 and going forward.”

Third Quarter 2026 Revenue Highlights and 2026 Revenue Guidance

  • Total revenue in the third quarter 2026 was $173 million. The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from new product launches.

  • CRYSVITA revenue in the third quarter 2026 was $109 million, consistent with expected ordering patterns. The company reaffirms its full year 2026 Crysvita revenue guidance of $500 million to $520 million.

  • DOJOLVI revenue in the third quarter 2026 was $30 million. The company reaffirms its full year 2026 Dojolvi revenue guidance of $100 million to $110 million.

  • EVKEEZA® revenue in the third quarter 2026 was $24 million, driven by increased demand from new country launches and early access.

  • MEPSEVII® revenue in the third quarter 2026 was $10 million.

Summary of Third Quarter 2026 Financial Results

| Selected Financial Data (dollars in millions, except per share amounts), (unaudited) | | | | |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Total revenues | $ | 173 | | | $ | 160 | | | $ | 523 | | | $ | 466 | |

| Operating expenses: | | | | | | | |

| Cost of sales | | 32 | | | | 28 | | | | 96 | | | | 80 | |

| Research and development | | 154 | | | | 216 | | | | 508 | | | | 547 | |

| Selling, general and administrative | | 97 | | | | 87 | | | | 273 | | | | 261 | |

| Total operating expenses | | 283 | | | | 331 | | | | 877 | | | | 888 | |

| Net loss | $ | (118 | ) | | $ | (180 | ) | | $ | (395 | ) | | $ | (446 | ) |

| Net loss per share, basic and diluted | $ | (1.16 | ) | | $ | (1.81 | ) | | $ | (3.89 | ) | | $ | (4.55 | ) |

Operating Expenses

Total operating expenses for the third quarter 2026 were $283 million, including $34 million of non-cash stock-based compensation.

Net Loss

Net loss for the third quarter 2026 was $118 million, or $1.16 per share basic and diluted, compared with a net loss for the third quarter 2025 of $180 million, or $1.81 per share basic and diluted.

Cash Balance and Net Cash Used in Operations Cash, cash equivalents, and marketable securities were $401 million as of September 30, 2026. For the three months ended September 30, 2026, net cash used in operations was $43 million.

In October 2026, the Company entered into two definitive agreements to sell the PRVs received upon the approval of GENGLYCOS and FAYUVI for a combined price of $413 million. The sale of the GENGLYCOS PRV closed last week and the FAYUVI PRV sale is expected to close later this month. Net proceeds from both sales are expected to be approximately $350 million.

Initiation of substantial expense reductions and reaffirming profitability in 2027

With the recent completion of late-stage development programs, including first-ever FDA approvals in glycogen storage disease type Ia (GSDIa) and Sanfilippo syndrome type A, Ultragenyx is entering a new stage focused on commercial execution and a smaller, more targeted R&D footprint. To support this transition, the company has initiated substantial headcount and expense reductions and expects to reduce 2027 R&D expenses to less than $350 million and 2027 SG&A expenses to less than $375 million. Savings actions include:

  • Reducing headcount by approximately 20%, resulting in a revised workforce of approximately 1,000 employees

  • Completing wind-down of all ongoing studies for GTX-102 for Angelman syndrome

  • Terminating UX701 for Wilson disease based on not achieving study goals

  • Reducing expenses across the company, including reduction of real estate footprint

In addition to executing these critical expense reductions, the company is focused on driving successful launches for GENGLYCOS and FAYUVI and continuing to grow current product revenues. R&D investments will be focused on delivering primary data from the responder endpoint of the ongoing Phase 3 study for DTX301 for ornithine transcarbamylase deficiency, determining if there is a viable path forward for UX143 (setrusumab) for osteogenesis imperfecta, and measured spending to progress early-stage programs for future INDs.

Fourth quarter 2026 financial results are expected to include approximately $25 million of severance and other non-recurring restructuring charges, and the reduction in force is expected to be substantially completed by the end of 2026. The company continues to anticipate achieving full-year GAAP profitability in 2027 and going forward.

Recent Corporate Updates and Upcoming Milestones

  • GENGLYCOS (pariglasgene brecaparvovec) AAV8 gene therapy for the treatment of glycogen storage disease type Ia (GSDIa): In August 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval for GENGLYCOS as a treatment for adult and pediatric patients eight years and older with GSDIa. The company received a PRV upon this approval and sold it for $210 million.

  • FAYUVI (rebisufligene etisparvovec) AAV9 gene therapy for the treatment of Sanfilippo syndrome type A (MPS IIIA): In September 2026, the FDA granted standard full approval for FAYUVI as a treatment of pediatric patients with Sanfilippo syndrome Type A. The company received a PRV upon this approval and, in October 2026, entered into a definitive agreement to sell the PRV for $203 million.

  • UX701 (rivunatpagene miziparvovec) AAV9 gene therapy for the treatment of Wilson disease: Additional data in the dose-finding stage of the Cyprus2+ study of UX701 for the treatment of Wilson disease, including data from the fourth dosing cohort, demonstrated clinical activity in some patients, but did not meet the criteria that the majority of patients achieve biochemical response and elimination of standard of care, to advance the program to the pivotal Phase 3, stage of development. UX701 demonstrated a favorable safety profile across all cohorts dosed. Data from the completed study is expected to be presented at an upcoming medical or scientific congress.

The company will terminate further development of this program and is working with clinical sites and patient advocacy groups to support the patient community through this transition.

  • UX016****novel prodrug for sialic acid used as a substrate replacement therapy for the treatment of GNE myopathy: The Phase 1/2 study is evaluating safety and dose of UX016 and its impact on muscle strength in adults with GNEM. The UX016 program is fully funded through clinical proof-of-concept by an external venture philanthropy agreement with a patient group, which supports all costs for the Phase 1/2 study and dosing will be initiated soon.

  • DTX301 (avalotcagene ontaparvovec) AAV8 gene therapy for the treatment of****Ornithine Transcarbamylase, or OTC, deficiency: The Phase 3 Enh3ance placebo-controlled study showed substantial improvement in ammonia control and reduction in the need for scavenger medicines along with profound improvement in global impression scale. The study continues with patients in both treatment and cross-over groups progressing through 64 weeks of follow-up to evaluate the second primary endpoint of the reduction in the use of ammonia scavengers and dietary management. Data are expected in the first half of 2027.

  • UX143 (setrusumab) monoclonal antibody for the treatment of osteogenesis imperfecta: Phase 3 data with pre- and post-hoc analyses were presented at the American Society for Bone and Mineral Research 2026 Annual Meeting showing a meaningful benefit on bone mineral density, fractures, and other endpoints in the two Phase 3 studies. The company will continue to engage regulatory agencies to determine the necessary data to support a regulatory filing and if there is a potential path forward for UX143.

Conference Call and Webcast Information

Ultragenyx will host a conference call today, Tuesday, November 3, 2026, at 2 p.m. PT/5 p.m. ET to discuss the third quarter financial results and provide a corporate update. The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.

About Ultragenyx

Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.

October 27, 2026

PDF Version

NOVATO, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, November 3, 2026, to discuss its financial results and corporate update for the quarter ending September 30, 2026.

The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.

About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

Ultragenyx Pharmaceutical Inc. — Other Events Bull 0 Bear 5 Legal

Other Events.

On October 19, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) and Baylor Research Institute (“BRI”) entered into a settlement agreement with Navinta LLC (“Navinta”) resolving patent litigation related to patents covering the Company’s DOJOLVI® (triheptanoin) oral liquid. The litigation, which was filed in the United States District Court for the District of New Jersey, resulted from the submission by Navinta of an Abbreviated New Drug Application (“ANDA”) to the U.S. Food and Drug Administration seeking approval to market a generic version of DOJOLVI in the United States. Under the terms of the settlement agreement, the Company will grant Navinta a non-exclusive, royalty-free license to market its generic version of DOJOLVI beginning January 1, 2033, which would be extended to July 1, 2033 if pediatric exclusivity is granted for DOJOLVI, subject to certain conditions and exceptions customary for agreements of this type. Similar patent litigation brought by the Company against other ANDA filers related to DOJOLVI remains pending in the U.S. District Court for the District of New Jersey. As required by law, the settlement agreement will be submitted to the U.S.

Prompts

Ultragenyx Pharmaceutical Inc. (ticker RARE), listed in United States.

Company History

Date Change Detail
Nov 6, 2017 Acquired Acquired Dimension Therapeutics, Inc. (CIK 1592288). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Ultragenyx Pharmaceutical Inc.

ETF Weight in ETF Shares Market value As of
TMFS 3.01% 69,581 $ 1.754M Aug 31, 2026
TSEL 0.96% 24,073 $ 803.797K Jun 30, 2026
HELX 0.61% 5,131 $ 171.324K Jun 30, 2026
MKTN short -0.41% -13,160 $ -439.412K Jun 30, 2026
ESSC 0.27% 3,948 $ 98.345K Jul 31, 2026
FSEG 0.14% 242 $ 8,080.38 Jun 30, 2026
CDX short -0.11% -16,951.7627 $ -283.094K Nov 17, 2026
FESM 0.10% 176,799 $ 5.903M Jun 30, 2026
RESM 0.10% 105 $ 3,505.95 Jun 30, 2026
TMSL 0.09% 71,898 $ 2.401M Jun 30, 2026
ENHU 0.01% 34 $ 540.60 Nov 16, 2026
MSSM 0.01% 1,551 $ 39.101K Aug 31, 2026
AVUQ 0.00% 384 $ 6,105.60 Nov 16, 2026